)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
OSE Immunotherapeutics
OSE Immunotherapeutics (OSE) investor relations material
OSE Immunotherapeutics Trading update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Trading update summary28 Sep, 2026
Executive summary
Cash position at June 30, 2026, was €11.1 million, with runway confirmed through December 2026.
Flexible bridge equity financing in May 2026 supports operations and is part of a broader financing strategy.
Publication of H1 2026 financial results postponed amid ongoing financing efforts.
Active engagement with institutional investors in the US and Europe to extend cash runway beyond 2026.
Financial highlights
Cash decreased from €17.0 million on March 31, 2026, to €11.1 million on June 30, 2026.
Current cash and bridge financing estimated sufficient to fund operations through December 2026, excluding potential milestone payments.
Outlook and guidance
Ongoing efforts to secure additional financing, including potential new partnerships and debt restructuring.
Cash runway expected through December 2026, with plans to extend further.
Tedopi's Phase 3 ARTEMIA trial enrolment on track for completion by end of December 2026; futility analysis now expected early 2027.
Subcutaneous formulation of lusvertikimab expected to reach validation by mid-2027; Phase 2 in chronic pouchitis planned for 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OSE Immunotherapeutics
- Lusvertikimab delivers strong phase II efficacy in UC and advances as a novel therapy for pouchitis.OSE
Study result - Tedopi and Lusvertikimab show strong clinical progress and financial stability supports future growth.OSEStatus update
- Significant revenue decline and net loss in 2025; cash runway until early Q4 2026.OSEH2 2025
- Four value levers and EUR 90M funding drive a three-year plan with strong financial discipline.OSEInvestor Update
- Revenue and cash fell, funding secured to Q4 2026 amid milestone delays and financing risks.OSEH1 2025
- Record H1 2024 revenue and profit driven by licensing deals and clinical milestones.OSEH1 2024
- Record income and major partnerships fuel OSE Immunotherapeutics' profitable 2024.OSEH2 2024
Next OSE Immunotherapeutics earnings date
H1 202615 Oct, 2026
OSE Immunotherapeutics
Next OSE Immunotherapeutics earnings date
H1 202615 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage